Evidence map›Paper›PMID 34902959›Full record

ArticleCancer research and treatment2022

Recommendations for the Use of Next-Generation Sequencing and the Molecular Tumor Board for Patients with Advanced Cancer: A Report from KSMO and KCSG Precision Medicine Networking Group.

Shinkyo Yoon, Miso Kim, Yong Sang Hong, Han Sang Kim, Seung Tae Kim, Jihun Kim, Hongseok Yun, Changhoon Yoo, Hee Kyung Ahn, Hyo Song Kim and 14 more

Erratum issuedOpen access · diamondAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Cancer research and treatment, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 14 papers.

0numbers the graph read from it
0cells of the map it votes in
14citing papers in PubMed
4.2field-weighted citation impact, top 4% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

14 citing papers in PubMed, 24 citations in OpenAlex.

  1. Review
  2. Review
  3. Review
  4. Molecular epidemiology and outcomes ofTranslational lung cancer research · 2026
    Article
  5. Article
  6. Article
  7. Review
  8. Review
  9. Article
  10. Article
  11. Article
  12. Article
  13. Article
  14. Somatic Mutations ofJournal of breast cancer · 2022
    Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

24 authors at 13 institutions in 1 country.

Shinkyo YoonDepartment of Oncology, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Korea.
Miso KimDepartment of Internal Medicine, Seoul National University Hospital, Seoul National University College of Medicine, Seoul, Korea.
Yong Sang HongDepartment of Oncology, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Korea.
Han Sang KimDivision of Medical Oncology, Yonsei Cancer Center, Yonsei University College of Medicine, Seoul, Korea.
Seung Tae KimDivision of Hematology-Oncology, Department of Medicine, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Korea.
Jihun KimDepartment of Pathology, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Korea.
Hongseok YunDepartment of Genomic Medicine, Seoul National University Hospital, Seoul National University College of Medicine, Seoul, Korea.
Changhoon YooDepartment of Oncology, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Korea.
Hee Kyung AhnDivision of Medical Oncology, Department of Internal Medicine, Gachon University Gil Medical Center, Incheon, Korea.
Hyo Song KimDivision of Medical Oncology, Yonsei Cancer Center, Yonsei University College of Medicine, Seoul, Korea.
In Hee LeeDepartment of Oncology/Hematology, Kyungpook National University Chilgok Hospital, Daegu, Korea.
In-Ho KimDivision of Medical Oncology, Department of Internal Medicine, Seoul St. Mary's Hospital, College of Medicine, The Catholic University of Korea, Seoul, Korea.
Inkeun ParkDivision of Medical Oncology, Department of Internal Medicine, Gachon University Gil Medical Center, Incheon, Korea.
Jae Ho JeongDepartment of Oncology, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Korea.
Jaekyung CheonDepartment of Medical Oncology, CHA Bundang Medical Center, CHA University School of Medicine, Seongnam, Korea.
Jin Won KimDivision of Hematology/Medical Oncology, Department of Internal Medicine, Seoul National University Bundang Hospital, Seoul National University College of Medicine, Seongnam, Korea.
Jina YunDivision of Medical Oncology, Department of Internal Medicine, Soonchunhyang University Bucheon Hospital, Bucheon, Korea.
Sun Min LimDivision of Medical Oncology, Yonsei Cancer Center, Yonsei University College of Medicine, Seoul, Korea.
Yongjun ChaCenter for Colorectal Cancer, National Cancer Center, Research Institute and Hospital, Goyang, Korea.
Se Jin JangDepartment of Pathology, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Korea.
Dae Young ZangDepartment of Internal Medicine, Hallym University Medical Center, Hallym University, Anyang, Korea.
Tae Won KimDepartment of Oncology, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Korea.
Jin Hyoung KangDivision of Medical Oncology, Department of Internal Medicine, Seoul St. Mary's Hospital, College of Medicine, The Catholic University of Korea, Seoul, Korea.
Jee Hyun KimDivision of Hematology/Medical Oncology, Department of Internal Medicine, Seoul National University Bundang Hospital, Seoul National University College of Medicine, Seongnam, Korea.
Asan Medical Center · KRUniversity of Ulsan · KRYonsei University · KRCatholic University of Korea · KRGachon University Gil Medical Center · KRSeoul National University Hospital · KRUlsan College · KRCHA University Bundang Medical Center · KRHallym University Medical Center · KRKyungpook National University Hospital · KRNational Cancer Center · KRSamsung Medical Center · KRSoonchunhyang University · KR

Funding

Ministry of Health and Welfare 1720150
6 · The paper itself

Abstract

Next-generation sequencing (NGS) is becoming essential in the fields of precision oncology. With implementation of NGS in daily clinic, the needs for continued education, facilitated interpretation of NGS results and optimal treatment delivery based on NGS results have been addressed. Molecular tumor board (MTB) is multidisciplinary approach to keep pace with the growing knowledge of complex molecular alterations in patients with advanced solid cancer. Although guidelines for NGS use and MTB have been developed in western countries, there is limitation for reflection of Korea's public health environment and daily clinical practice. These recommendations provide a critical guidance from NGS panel testing to final treatment decision based on MTB discussion.

Indexed as

High-Throughput Nucleotide SequencingHumansMedical OncologyNeoplasmsPractice Guidelines as TopicPrecision MedicineRepublic of KoreaSocieties, MedicalAdvanced solid cancerGenomic alterationsMolecular tumor boardNext-generation sequencingPrecision Medicine

Identifiers

PMID34902959
PMCPMC8756119
OpenAlexW4200007165

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.